**BACKGROUND**

- Cannabis use is common among PWH. Yet, definitive evidence on whether cannabis benefits or harms the health of PWH is limited.
- This is due in part to studies relying on self-reported cannabis use and cross-sectional designs.

**STUDY OBJECTIVES**

To determine:

- The feasibility of 28-days of monitored abstinence from cannabis use in PWH
- Whether cannabis abstinence/reduction is associated with depression, anxiety symptoms, inflammation, sleep, pain and HIV viral load.

**METHODS**

- **Study design**: Single-arm feasibility study
- **Target sample size**: 45 PWH
- **Eligibility criteria**:
  - 18+ years of age,
  - Self-report weekly cannabis use
  - Positive UTOX for cannabinoids.
- **Intervention**: 28-day contingency management (CM) program. Participants will be provided with escalating financial incentives for study visit attendance and cannabis-negative urine samples
- **Primary endpoints**:
  - # Subjects enrolled
  - # Subjects completing the CM program
  - # Subjects achieving 28-days of sustained cannabis abstinence
- **Secondary endpoints**:
  - Depression and anxiety symptoms
  - Pain symptoms
  - Sleep
  - Inflammation
  - HIV viral load

**DISCUSSION**

- This study will provide important feasibility data on enrolling and retaining PWH who use cannabis in a clinical study.

**ACKNOWLEDGEMENTS**

Chukwuemeka N. Okafor is supported by the National Institute on Drug Abuse (K01-DA047912). The contents of this publication are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health (NIH).

ClinicalTrials.gov #: NCT04866004